XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
May 03 2021 - 8:32AM
Dow Jones News
By Michael Dabaie
XOMA Corp. said it earned a $500,000 milestone from Janssen
Biotech Inc. as a result of the first patient dosed in a Phase 3
clinical trial evaluating one of Janssen's biologic assets.
"Cetrelimab is the second molecule to advance to Phase 3
development since we pivoted to become a biotech royalty aggregator
in 2017," said XOMA Chief Executive Jim Neal.
Under the terms of the agreement with Janssen, XOMA has the
potential to receive additional regulatory milestone payments
should Janssen achieve marketing approval, and upon
commercialization will receive a royalty on future commercial
sales, XOMA said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 03, 2021 08:17 ET (12:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
